O vert and subclinical hypothyroidism are risk factors for atherosclerosis and cardiovascular disease (CVD). 1, 2 Emerging evidence further suggests that variations in thyroid hormone levels within the euthyroid range may also be associated with CVD risk. Low-normal thyroid function has been associated with coronary atherosclerosis measured by coronary angiography and with increased carotid intimamedia thickness (CIMT) and severity of carotid plaque, [3] [4] [5] [6] but these findings were inconsistent in other studies. [7] [8] [9] The evidence on the association between thryroid hormone levels in the euthyroid range and atherosclerosis, however, is largely based on relatively small cross-sectional studies, often with highly selected clinical samples. In addition, few studies have reported the association between hyperthyroidism and atherosclerosis, but some evidence suggested that hyperthyroidism was also associated with increased CIMT. triiodothyronine (FT3) levels were not measured in this study, and the relatively small sample size may have limited their ability to detect an association in women.
The objective of this study was thus to evaluate the crosssectional association of FT4, FT3, and thyroid-stimulating hormone (TSH) with the prevalence of CAC in a large sample of apparently healthy men and women with normal thyroid hormone levels participating in the Kangbuk Samsung Health Study.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
The average age of study participants was 41.2 years, and 83.2% of them were men (Table 1; Figure 1 ). The average FT4, FT3, and TSH levels were 1.3 ng/dL, 3.3 pg/mL, and 2.0 μLU/mL, respectively. For thyroid hormone levels, the Spearman correlation coefficients were 0.38 between FT4 and FT3, −0.13 between FT4 and TSH, and −0.09 between FT3 and TSH. The prevalences of CAC scores of 0, 1 to 100, and 100 were 86.9%, 11.1%, and 2.0%, respectively.
FT4 and TSH levels showed significant inverse associations with CAC scores, whereas FT3 was only marginally associated with CAC. In Tobit regression analysis, the CAC ratios comparing the highest versus the lowest quartiles of thyroid hormones were 0.74 (95% confidence interval, 0.60-0.91; P for trend <0.001) for FT4, 0.81 (0.66-1.00; P for trend=0.05) for FT3, and 0.78 (0.64-0.95; P for trend=0.01) for TSH (Table 2 ). In multivariable adjusted logistic regression, the odds ratios for detectable CAC (CAC >0) comparing the highest versus the lowest quartiles of thyroid hormones were 0.87 (0.79-0.96; P for linear trend <0.001) for FT4, 0.90 (0.82-0.99; P for linear trend=0.02) for FT3, and 0.91 (0.83-1.00; P for linear trend=0.03) for TSH, respectively (Table 3) .
Results from multinomial logistic regression modeling CAC 1 to 100 (versus CAC=0) and CAC >100 (versus CAC=0) were consistent with findings from Tobit and logistic regression models (see Table I in the online-only Data Supplement for details). Spline regression analyses also confirmed that FT4 and TSH were inversely associated with CAC scores, with approximately linear dose-response relationships (P value for nonlinear spline terms >0.1; Figure 2 ).
In stratified analyses by prespecified subgroups, the associations between thyroid hormones and CAC scores were similar across examined subgroups, although the association between FT4 and CAC appeared to be present in men but not in women (P for interaction by sex=0.02; Figure 3 ). When further stratified by menopausal status among women, the associations were not different among pre-and postmenopausal women (data not shown). 
Discussion
In this large study of euthyroid men and women, serum FT4 and TSH levels within the normal range were inversely associated with the prevalence of subclinical coronary artery disease and with the degree of coronary calcification, whereas the inverse association between FT3 and CAC scores was only marginal. The association of FT4 and TSH with coronary artery atherosclerosis was present even in participants at low cardiovascular risk defined by the Framingham Risk Score. Our findings suggest that variations in thyroid hormone levels, even within the clinical euthyroid range, may be important in the pathogenesis of coronary atherosclerosis. Overt and subclinical hypothyroidism are well-established risk factors for atherosclerosis. 1, 2 Patients with subclinical hypothyroidism are more likely to have an increased CIMT and a higher prevalence of carotid plaques, 1, 17 and levothyroxine replacement therapy in these patients reduced CIMT and improved cardiovascular risk factor levels and endothelial function. 18, 19 Studies of the association between thyroid hormone levels in the euthyroid range and atherosclerosis, however, have been inconsistent. Several cross-sectional studies of euthyroid individuals found that FT4 levels were inversely associated with CIMT and with the severity of carotid plaque, [3] [4] [5] but these findings were not confirmed in another cross-sectional study of 1588 euthyroid individuals. 7 Among euthyroid patients referred for coronary angiography to evaluate chest pain, 1 study found that FT4 and FT3 were inversely associated and TSH was positively associated with coronary artery stenosis, 6 whereas other studies reported a positive association between FT4 and coronary atherosclerosis 8 or no association. 9 These studies, however, were limited by their relatively small sample sizes and the selected nature of study participants.
In the only study of the association between thyroid hormone levels and CAC in euthyroid individuals, Kim et al 16 (n=669) found that FT4, but not TSH, was inversely associated with CAC in men but not in women. Our study, with a much larger sample size (n=41 403), showed that both FT4 and TSH were inversely associated with CAC scores. Interestingly, the association between FT4 and coronary calcification in our study was also restricted to men. Few women in our study, however, had a CAC >0 in our study (n=412; 6%) as compared with men (n=5014; 15%), and therefore we might still be underpowered to detect an association among women in spite of our large sample size. Participants in the current analysis were on average 13 years younger and had lower 10-year Framingham Risk Scores compared with participants in the Kim et al 16 study, indicating that variations in thyroid hormones within the euthyroid range may be important in the pathogenesis of atherosclerosis even in young subjects at low overall cardiovascular risk.
Our findings for FT4 may have important clinical implications. The association between low-normal FT4 and coronary calcification is in line with emerging evidence reporting associations between low-normal FT4 levels and several cardiovascular risk factors including dyslipidemia, insulin resistance, and hypertension, indicating that individuals CAC score ratios were derived from Tobit regression models using ln(CAC+1) as the outcome. CAC indicates coronary artery calcium; FT3, free triiodothyronine; FT4, free thyroxin; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; and TSH, thyroid-stimulating hormone. *Model 1: Adjusted for age, sex, calendar year of examination, and study center. †Model 2: Further adjusted for smoking status, alcohol consumption, vigorous exercise, and body mass index. ‡Model 3: Further adjusted for total cholesterol, HDL cholesterol, triglycerides, HOMA-IR, high-sensitivity C-reactive protein, hypertension, diabetes mellitus, and use of lipid-lowering medication.
§P value for linear trend using an ordinal variable with the median thyroid hormone level in each quartile. with low-normal FT4 levels are at increased CVD risk compared with truly euthyroid individuals. 20, 21 Individuals with low-normal levels of FT4 may require careful follow-up, assessment of potential risk of CVD, and evaluation of the overall health status. The clinical management of these individuals should be addressed in clinical trials, particularly among those at high risk for CVD who may be considered for randomized clinical trials of thyroid hormone replacement therapy Several mechanisms may explain an increased prevalence of CAC with low-normal FT4 and FT3 levels. Decreased thyroid hormone levels may promote atherosclerosis via unfavorable changes in metabolic factors, including a more atherogenic lipid profile, increased insulin resistance, hypertension, lowgrade inflammation, and impaired endothelial function. [20] [21] [22] [23] Indeed, low-normal FT4 was associated with higher levels of total cholesterol, triglycerides, insulin resistance, and lower levels of high-density lipoprotein cholesterol in our study sample (data not shown). Interestingly, low-normal FT3 was associated with higher levels of total and low-density lipoprotein cholesterol, but also slightly higher levels of high-density lipoprotein cholesterol and lower levels of triglycerides and insulin resistance, which may explain why the association between FT3 and CAC was only marginal in our study. In addition, the increased prevalence of CAC with low levels of FT4 was evident even after adjusting for multiple cardiometabolic factors, suggesting that the mechanisms linking low FT4 levels to coronary atherosclerosis may be partly independent of traditional cardiovascular risk factors. Experimental studies have shown direct antiatherosclerotic effects from thyroid hormones including blood vessel dilatation, suppression of vascular smooth muscle cell proliferation via inhibition of angiotensin II-induced activation of cAMP response element-binding protein, inhibition of collagen-induced platelet aggregation, and facilitation of matrix Gla protein gene expression in smooth muscle cells (an inhibitor of vascular calcification). [24] [25] [26] [27] However, because lipids and other cardiovascular risk factors were only measured at a single point in time in our study, it is also possible that the adjustment for these cardiometabolic factors may not fully account for their cumulative effects over time or residual confounding because of measurement error.
The inverse association between TSH and CAC is somewhat perplexing, because many previous studies have shown that subclinical hypothyroidism is associated with increased CVD risk, and our own analysis also found an inverse association between FT4 and CAC. However, our study was not the first to report an inverse association between TSH and CAC. Odds ratios were derived from logistic regression models using binary CAC (CAC=0 vs >0) as the outcome. CAC indicates coronary artery calcium; FT3, free triiodothyronine; FT4, free thyroxin; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; and TSH, thyroid-stimulating hormone. *Model 1: Adjusted for age, sex, calendar year of examination, and study center. †Model 2: Further adjusted for smoking status, alcohol consumption, vigorous exercise, and body mass index. ‡Model 3: Further adjusted for total cholesterol, HDL cholesterol, triglycerides, HOMA-IR, high-sensitivity C-reactive protein, hypertension, diabetes mellitus, and use of lipid-lowering medication.
§P value for linear trend using an ordinal variable with the median thyroid hormone level in each quartile.
In a study of 669 euthyroid participants, TSH was inversely, albeit nonsignificantly, associated with CAC. 16 In another study of 141 patients with type 2 diabetes mellitus but free from clinical CVD, TSH was inversely correlated with CAC, and low TSH level was associated with higher CAC scores even after multiple regression. 28 Although the exact underlying mechanism is still elusive, evidence from experimental and clinical data may provide some insights into this association. Adjusted coronary artery calcium (CAC) score ratios comparing the sex-specific 90th to the 10th percentiles of free thyroxin (FT4), free triiodothyronine (FT3), and thyroid-stimulating hormone (TSH) in prespecified subgroups. CAC score ratios were derived from Tobit regression models using ln(CAC+1) as outcome, adjusting for age, sex, calendar year of examination, study center, smoking status, alcohol consumption, vigorous exercise, body mass index, total cholesterol, high-density lipoprotein cholesterol, triglycerides, homeostasis model assessment of insulin resistance, high-sensitivity C-reactive protein, hypertension, diabetes mellitus, and use of lipid-lowering medication. The 10th and 90th percentiles in women were 1.03 and 1.38 ng/dL for FT4, 2.55 and 3.38 pg/mL for FT3, and 0.98 and 3.54 μLU/mL for TSH. The corresponding 10th and 90th percentiles in men were 1.13 and 1.52 ng/dL for FT4, 2.93 and 3.81 pg/mL for FT3, and 0.90 and 3.31 μLU/mL for TSH. Adjusted coronary artery calcium (CAC) score ratios by levels of free thyroxin (FT4), free triiodothyronine (FT3), and thyroidstimulating hormone (TSH). Curves represent adjusted CAC score ratios from Tobit regression analyses using ln(CAC+1) as outcome with restricted quadratic splines for thyroid hormone levels with knots at the 5th, 50th, and 95th percentiles of their sample distributions. Models were adjusted for age, sex, calendar year of examination, study center, smoking status, alcohol consumption, vigorous exercise, body mass index, total cholesterol, high-density lipoprotein cholesterol, triglycerides, homeostasis model assessment of insulin resistance, high-sensitivity C-reactive protein, hypertension, diabetes mellitus, and use of lipid-lowering medication. The reference values (diamond dots) were set at the 10th percentile of the thyroid hormone distributions. Histograms represent the frequency distributions of thyroid hormone levels.
First, TSH has a direct effect on bone metabolism via binding to TSH receptor on the osteoblast and osteoclast precursors. 29 Studies have further showed that the process of calcium accumulation in blood vessels resembles bone formation, and a main mechanism underlying vascular calcification is differentiation of vascular smooth muscle cells into osteoblast-like cells that promote atherosclerotic calcium build-up. 30, 31 Taken together with the fact that TSH receptors have also been found on coronary artery smooth muscle cells, these data suggest that TSH may have a direct effect on vascular calcification via TSH receptor in such cells independently of the level of FT4 or FT3, and there may be different mechanisms and pathways underlying the associations between TSH and CAC (ie, through direct modulation of vascular calcification via TSH receptor) and FT4 and CAC (ie, through hyperlipidemia and insulin resistance). 32 Second, the correlations between TSH and FT4 or FT3 in our study were relatively low (−0.13 between FT4 and TSH, and −0.09 between FT3 and TSH), indicating that patients with high levels of TSH did not necessarily have low levels of FT4 or FT3 (eg, among participants in the top 2 quartiles of TSH, 43% were also in the top 2 quartiles of FT4), and TSH and FT4 may partially independently correlate with CAC among euthyroid individuals. Third, in individuals without known thyroid disease, decreased TSH levels were independently associated with higher CIMT 10 and with elevated plasma fibrinogen, a risk factor for atherosclerosis and CVD. 33, 34 Finally, low-normal TSH may represent a transient stage in new-onset autoimmune thyroid disease, which has been related to atherosclerosis via chronic inflammation and endothelial dysfunction. 35 Further experimental and clinical research is needed to validate our findings in other study populations and to better understand the biological mechanisms underlying the association between TSH and CAC.
Several limitations of our study need to be considered. First, the cross-sectional design limited our ability to make statements about the causality of the associations. However, we carefully selected participants with no known thyroid conditions, and we used a subclinical marker of CVD as outcome, minimizing the risk of reverse causation. Second, reverse T3 was not measured in our study, and we were not able to assess whether nonthyroidal illness may impact the inverse association between TSH and CAC. However, because the majority of the study participants were apparently healthy, middle-aged individuals with low burden of comorbidities, the likelihood of nonthyroidal illness in our population was low. Third, we did not measure thyroid antibodies and could not assess the role of autoimmune thyroid disease. Fourth, our study population consisted of apparently healthy young and middle-aged Korean men and women, which may limit the generalizability of our findings to other populations. Lastly, the relatively small number of participants with CAC >0, particularly among women, may limit our ability to detect a statistically significant association.
Our study also had several strengths. First, the Kangbuk Samsung Health Study is by far the largest population-based study evaluating the association between thyroid hormones and CAC.
Second, because participants in our study were relatively young and apparently healthy with low burden of comorbidities, associations identified in our analysis were more robust and less likely to be biased by confounding factors. Third, we measured FT3 in addition to FT4 and TSH, allowing for a detailed characterization of the thyroid status and reduce misclassification. Fourth, we used high-quality clinical, imaging, and laboratory procedures, with stringent quality control for data acquisition and analysis. Finally, we also measured an extensive panel of health-related variables, allowing for detailed adjustment of potential confounders.
In conclusion, in a large cohort of apparently healthy young and middle-aged euthyroid men and women, low-normal FT4 and TSH were associated with a higher prevalence of subclinical coronary artery disease and with a greater degree of coronary calcification. Our findings suggest that variation in thyroid function, even within the clinical euthyroid range, may be important in the pathogenesis of atherosclerosis. Together with other evidence linking low-normal FT4 levels with increased cardiovascular risk factors, 20, 21 our findings call for a more careful follow-up, assessment of potential CVD risk, and detailed evaluation of the role of thyroid hormone therapy in preventing atherosclerosis in individuals with lownormal FT4.
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Overt and subclinical hypothyroidism are well-established risk factors for atherosclerosis and cardiovascular disease. Emerging evidence further suggests that variations in thyroid hormone levels within the euthyroid range may also be associated with cardiovascular risk. Our study examined the association between thyroid hormones and coronary artery calcium, a reliable marker of subclinical atherosclerosis, in a large sample of apparently healthy young and middle-aged men and women with normal thyroid hormone levels (n=41 403). We found that low-normal free thyroxin and low-normal thyroid-stimulating hormone were associated with a higher prevalence of subclinical coronary artery disease and with a greater degree of coronary calcification. These findings call for a more careful follow-up, assessment of potential cardiovascular disease risk, and detailed evaluation of the role of thyroid hormone therapy in preventing atherosclerosis in individuals with low-normal free thyroxin.
Significance

